TherapeuticsMD (TXMD) Non Operating Income (2010 - 2026)
TherapeuticsMD (TXMD) posted Non Operating Income of $826000.0 for Q1 2026, down 15.02% on a QoQ basis from $972000.0 in Q4 2025, and up 34.75% year-over-year from $613000.0 in Q1 2025.
TherapeuticsMD (TXMD) Non Operating Income (2010 - 2026) Analysis & Trends
TherapeuticsMD's Non Operating Income history runs 17 years deep, the most recent figure standing at $826000.0 for Q1 2026.
- Quarterly Non Operating Income rose 34.75% year-over-year to $826000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 8.1% YoY) and the FY2025 annual result came in at $3.7 million, down 0.85% from the prior year.
- Non Operating Income was $826000.0 for Q1 2026 at TherapeuticsMD, down from $972000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $1.7 million in Q2 2024 and bottomed at -$22.8 million in Q1 2022.
- A 5-year average of -$834764.7 and a median of $357000.0 in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income sank 125.55% — and 2024, when it soared 2898.28%.
- TherapeuticsMD's Non Operating Income stood at $11000.0 in 2022, then surged by 145.45% to $27000.0 in 2023, then surged by 2622.22% to $735000.0 in 2024, then jumped by 32.24% to $972000.0 in 2025, then slipped by 15.02% to $826000.0 in 2026.
- Business Quant data shows TXMD's Non Operating Income at $826000.0 in Q1 2026, $972000.0 in Q4 2025, and $912000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | -216.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 20.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -7.50 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 53.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | TherapeuticsMD | 278,799.99 | -8.14 Mn | - | 826,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 826,000.00 |
| Dec 31, 2025 | 972,000.00 |
| Sep 30, 2025 | 912,000.00 |
| Jun 30, 2025 | 1.24 Mn |
| Mar 31, 2025 | 613,000.00 |
| Dec 31, 2024 | 735,000.00 |
| Sep 30, 2024 | 567,000.00 |
| Jun 30, 2024 | 1.74 Mn |
| Mar 31, 2024 | 333,000.00 |
| Dec 31, 2023 | 27,000.00 |
| Sep 30, 2023 | 339,000.00 |
| Jun 30, 2023 | 58,000.00 |
| Mar 31, 2023 | 357,000.00 |
| Dec 31, 2022 | 11,000.00 |
| Sep 30, 2022 | -112,000.00 |
| Jun 30, 2022 | -16,000.00 |
| Mar 31, 2022 | -22.79 Mn |
| Dec 31, 2021 | 25.35 Mn |
| Sep 30, 2021 | -7.50 Mn |
| Jun 30, 2021 | -7.47 Mn |